Metaphore Biotechnologies Names Former Pfizer CFO Frank D’Amelio and Biotech Entrepreneur Pascal Deschatelets to Board

0
53

CAMBRIDGE, Mass.– Metaphore Biotechnologies, a Flagship Pioneering company developing antibody-based medicines for complex diseases, has appointed former Pfizer Chief Financial Officer Frank D’Amelio and biotechnology entrepreneur Pascal Deschatelets, Ph.D., as independent members of its board of directors.

The appointments come as the Cambridge-based biotechnology company prepares to advance its drug development programs toward clinical testing.

Metaphore is developing a platform designed to create antibody medicines capable of activating biological targets, modifying cellular signaling and engaging multiple targets simultaneously. The company aims to use insights into how biological systems behave in living cells to develop new treatments for complex diseases.

D’Amelio brings more than four decades of experience in corporate finance, pharmaceutical operations and business development, including nearly 15 years as Pfizer’s chief financial officer.

Deschatelets, a co-founder of Apellis Pharmaceuticals, has extensive experience in biotechnology company formation, drug discovery and the development of treatments based on emerging scientific approaches.

“Frank brings financial judgment tested through major transactions and the operating experience of delivering medicines to patients worldwide. Pascal brings a rigorous scientific lens to the decisions that turn novel biology and platform potential into new medicines,” said Lovisa Afzelius, Ph.D., MBA, Co-Founder and Board Chair, Metaphore and General Partner, Flagship Pioneering.

“Along with the other Board members and leadership team, they will help align Metaphore’s scientific ambition with the development strategy, organizational capabilities, and capital needed to build a successful medicines company.”

Deschatelets co-founded Apellis Pharmaceuticals, where he served as chief operating officer for more than a decade before becoming chief scientific officer.

During his tenure, he helped establish the company’s scientific direction and advance multiple first-in-class therapies, including the first approved treatment for geographic atrophy, an advanced form of age-related macular degeneration.

Apellis was acquired by Biogen in 2026 in a transaction valued at approximately $5.6 billion upfront.

Deschatelets also co-founded Potentia Pharmaceuticals, which developed an ocular complement program that was subsequently licensed to Alcon.

He is listed as an inventor on more than 90 patents and has authored more than 40 scientific publications.

“Metaphore has created a compelling system for learning from biology as it behaves in living cells, then using that information to guide antibody design,” said Deschatelets.

“A platform becomes meaningful when it informs the choices a company makes about its medicines. I look forward to working with the Board and leadership team as they turn those insights into programs with a clear scientific rationale, medical value, and a path to patients.”

D’Amelio spent nearly 15 years as CFO of Pfizer, overseeing major acquisitions, partnerships and corporate restructuring initiatives.

During his tenure, he helped lead transactions valued at nearly $200 billion, including Pfizer’s acquisitions of Wyeth, Hospira, Anacor and Medivation.

He also played a role in establishing Zoetis as an independent animal health company and helped oversee the creation of Pfizer’s consumer health joint venture with GSK.

In addition, D’Amelio was involved in combining Pfizer’s Upjohn business with Mylan to form Viatris.

His responsibilities at Pfizer eventually expanded to include business operations and global supply, including oversight of manufacturing activities during the initial rollout of COVID-19 vaccines.

D’Amelio currently serves on the boards of Zoetis, Humana, Hewlett Packard Enterprise, Viatris and Sail Biomedicines.

“Decisions about how a medicine will be financed, manufactured, and supplied deserve attention well before it reaches the clinic,” said D’Amelio.

“I’m looking forward to working with Metaphore to build those requirements into program selection, investment decisions, and development plans from the outset, so the company becomes an organization that can carry its therapeutic platform potential through to patients.”

The addition of D’Amelio and Deschatelets gives Metaphore experience spanning pharmaceutical commercialization, corporate finance, scientific innovation and clinical development as the company works to translate its antibody technology into potential therapies.

Metaphore was established through Flagship Pioneering, the Cambridge-based life sciences venture creation firm known for founding and developing biotechnology companies.

The company is focused on developing antibody medicines that interact with disease-related biological targets in ways that could expand the therapeutic applications of antibody-based treatments.

Leave A Reply

Please enter your comment!
Please enter your name here